Cirius Therapeutics, a clinical-stage pharmaceutical company which is developing a next-generation insulin sensitizer for the treatment of nonalcoholic steatohepatitis. Through its novel insulin sensitizing mechanism of action, the insulin sensitizer has a potential to resolve the underlying pathophysiology of NASH.